ReviewMolecular therapy. Nucleic acids2026
Mammalian therapeutic riboswitches: Engineering and custom ligands.
Review in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulation with riboswitches, which induce or repress gene expression in response to a ligand, is moving from proof-of-concept studies to robust clinical-grade gene therapies. These initial stages in RNA-based precision medicine will soon benefit from the next generation of riboswitches, whose engineering results from the combination of deep learning, structural biology, and innovative selection technologies. Recent breakthroughs in these strategies now allow for the identification of riboswitches responsive to wisely chosen pre-selected ligands. Selection of the best RNA-friendly and clinically relevant ligands is within the focus of this review. We analyze natural riboswitches in bacteria and eukaryotes and their distinct ligands. We describe how the field of riboswitch design has moved from traditional to novel strategies for identifying switches that function to regulate expression
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.